Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kairos Pharma, Ltd. ( (KAPA) ) has shared an update.
On February 26, 2026, Kairos Pharma, Ltd. announced it had signed a term sheet with privately held Celyn Therapeutics, Inc. to acquire worldwide rights to two clinical-stage small-molecule oncology assets for non-small cell lung cancer: CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. The contemplated deal would significantly expand Kairos’s pipeline in the multi-billion-dollar lung cancer market by enabling a dual-target strategy against EGFR mutations and MET-mediated resistance, positioning the company to develop potentially best-in-class monotherapies and combination regimens that address major resistance mechanisms in EGFR-mutant NSCLC and potentially enhance its competitive standing in the rapidly growing kinase inhibitor segment.
The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd., based in Los Angeles and listed on the NYSE American under the ticker KAPA, is a clinical-stage biopharmaceutical company focused on innovative oncology therapeutics that aim to overcome drug resistance and immune suppression in cancer. Its lead product candidate, ENV-105, is an antibody targeting CD105 that is currently in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, and it has not yet been approved by regulators as safe or effective.
Average Trading Volume: 144,825
Technical Sentiment Signal: Sell
Current Market Cap: $11.91M
See more data about KAPA stock on TipRanks’ Stock Analysis page.